In Products, saving lives
Products saving lives

Tackling epilepsy: a strong commitment for UCB

Brain diseases affect one in six people around the world, with a wide range of conditions affecting the central nervous system, making unlocking the science behind them complicated.

UCB is committed to looking for new ways to help patients living with neurological diseases. One area in which UCB has been working for decades is epilepsy. While it is the most common serious neurological condition, it manifests itself in different ways in different patients. To date, more than 100 different epilepsy syndromes have been identified.

For patients, the types and frequency of seizure vary greatly. Some are short, like muscle jerks, while others are prolonged convulsions. For patients battling epilepsy, regaining control – and getting seizures under control – is often a primary goal.

The biopharmaceutical sector has come a long way in the treatment of epilepsy. Today, nearly half of patients newly diagnosed with the condition become seizure-free with their first anti-epileptic drug.

But for one in three patients, seizures remain uncontrolled because no available treatment works for them. These are the great challenges that UCB is continuing to tackle through industry-wide innovation and collaboration. Breakthrough science and technology can help unlock better ways to care for and treat patients living with epilepsy. Whether it is helping to find a therapy that works for an individual patient faster or finding new ways to treat the root cause of disease, UCB is committed to continuing to unlock the science and find new ways to improve the lives of patients.

Source: This article was originally published on


Send this to a friend